Literature DB >> 15896207

HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing.

A M Martin1, D Nolan, S Mallal.   

Abstract

Susceptibility to abacavir hypersensitivity (ABC HSR) is strongly associated with alleles carried on the 57.1 ancestral haplotype including HLA-B*5701 and Hsp70 Hom M493T. In one study, prospective testing for HLA-B*5701 and exclusion of individuals carrying this allele, from receiving abacavir, substantially lowered the incidence of ABC HSR to 0% (95% confidence interval 0-0.075%). The presence of HLA-B*5701 is usually detected by standard serological tests and by molecular genetic methods such as sequence-based typing (SBT). While the former test cannot discriminate between HLA-B57 subtypes, the expensive SBT may not be readily available in all laboratories. Hence, an alternate method was developed to detect HLA-B*5701 using allele and group-specific polymerase chain reaction-sequence-specific primers (PCR-SSP) typing. This PCR-SSP-typing method positively amplified all HLA-B*5701 alleles in concordance with their SBT-assigned typing. This multiplexed SSP assay was able to distinguish between HLA-B*5701 (n = 10) and closely related HLA-B57 alleles B*5702 (n = 2), -B*5703 (n = 1), -B*5704 (n = 1) alleles and non-HLA-B*57 alleles (n = 61). In conclusion, this method of HLA-B*5701 detection is a rapid and accurate typing method with high specificity, sensitivity and reproducibility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896207     DOI: 10.1111/j.1399-0039.2005.00401.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  13 in total

1.  Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK.

Authors:  S T Sadiq; M Pakianathan
Journal:  Sex Transm Infect       Date:  2006-11-10       Impact factor: 3.519

Review 2.  Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy.

Authors:  Bente Magny Bergersen
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Rapid Near Point-of-Care Assay for HLA-B*57:01 Genotype Associated with Severe Hypersensitivity Reaction to Abacavir.

Authors:  Jackson J Wallner; Ingrid A Beck; Nuttada Panpradist; Parker S Ruth; Humberto Valenzuela-Ponce; Maribel Soto-Nava; Santiago Ávila-Ríos; Barry R Lutz; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2021-11-30       Impact factor: 2.205

Review 4.  Successful translation of pharmacogenetics into the clinic: the abacavir example.

Authors:  Elizabeth Phillips; Simon Mallal
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 5.  Abacavir pharmacogenetics--from initial reports to standard of care.

Authors:  Michael A Martin; Deanna L Kroetz
Journal:  Pharmacotherapy       Date:  2013-05-03       Impact factor: 4.705

6.  A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno.

Authors:  C Senatore; B Charlier; A Truono; R Punzi; F D'Aniello; N Boffa; V Izzo; V Conti; G Russomanno; V Manzo; A Filippelli; M Mazzeo
Journal:  Transl Med UniSa       Date:  2014-12-19

7.  Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.

Authors:  Ward De Spiegelaere; Jan Philippé; Karen Vervisch; Chris Verhofstede; Eva Malatinkova; Maja Kiselinova; Wim Trypsteen; Pawel Bonczkowski; Dirk Vogelaers; Steven Callens; Jean Ruelle; Kabamba Kabeya; Stephane De Wit; Petra Van Acker; Vicky Van Sandt; Marie-Paule Emonds; Paul Coucke; Erica Sermijn; Linos Vandekerckhove
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

Review 8.  Pharmacogenetics of drug hypersensitivity.

Authors:  Elizabeth J Phillips; Simon A Mallal
Journal:  Pharmacogenomics       Date:  2010-07       Impact factor: 2.533

9.  The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods.

Authors:  Laura Stocchi; Raffaella Cascella; Stefania Zampatti; Antonella Pirazzoli; Giuseppe Novelli; Emiliano Giardina
Journal:  Curr Genomics       Date:  2012-06       Impact factor: 2.236

10.  Individualization of antiretroviral therapy.

Authors:  Rebecca Pavlos; Elizabeth J Phillips
Journal:  Pharmgenomics Pers Med       Date:  2011-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.